Abstract
Cardiovascular disease is the leading cause of death in the United States and developing world. Experimental and clinical studies have demonstrated that a number of interventions including brief periods of ischemia or hypoxia and certain endogenous factors such as opioids, bradykinin, growth factors or pharmacological agents are capable of protecting the heart against post-ischemic contractile dysfunction, arrhythmias and myocardial infarction. This conventional cardioprotection occurs via an autocrine or paracrine action in which these protective factors are released from the heart to act upon itself. Over the last ten years, a growing body of evidence indicates that a brief ischemic insult on one organ releases endogenous factors that protect other organs against a prolonged ischemic insult. This phenomenon, termed remote preconditioning or preconditioning at a distance, implicates an endocrine action, and may involve humoral or neuralendocrine signaling. This review will summarize the endocrine factors identified and implicated in this inter-organ cytoprotection.
Keywords: Remote preconditioning, humoral, neurogenic, ischemia-reperfusion injury, endocrine factors, experimental studies, clinical studies
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Remote Preconditioning- Endocrine Factors in Organ Protection Against Ischemic Injury
Volume: 7 Issue: 3
Author(s): Craig S. Bolte, Siyun Liao, Garrett J. Gross and Jo El J. Schultz
Affiliation:
Keywords: Remote preconditioning, humoral, neurogenic, ischemia-reperfusion injury, endocrine factors, experimental studies, clinical studies
Abstract: Cardiovascular disease is the leading cause of death in the United States and developing world. Experimental and clinical studies have demonstrated that a number of interventions including brief periods of ischemia or hypoxia and certain endogenous factors such as opioids, bradykinin, growth factors or pharmacological agents are capable of protecting the heart against post-ischemic contractile dysfunction, arrhythmias and myocardial infarction. This conventional cardioprotection occurs via an autocrine or paracrine action in which these protective factors are released from the heart to act upon itself. Over the last ten years, a growing body of evidence indicates that a brief ischemic insult on one organ releases endogenous factors that protect other organs against a prolonged ischemic insult. This phenomenon, termed remote preconditioning or preconditioning at a distance, implicates an endocrine action, and may involve humoral or neuralendocrine signaling. This review will summarize the endocrine factors identified and implicated in this inter-organ cytoprotection.
Export Options
About this article
Cite this article as:
Bolte S. Craig, Liao Siyun, Gross J. Garrett and Schultz J. Jo El, Remote Preconditioning- Endocrine Factors in Organ Protection Against Ischemic Injury, Endocrine, Metabolic & Immune Disorders - Drug Targets 2007; 7 (3) . https://dx.doi.org/10.2174/187153007781662585
DOI https://dx.doi.org/10.2174/187153007781662585 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Efficacy of Chemoembolization of Hepatocellular Carcinoma with Drug Eluting Beads
Recent Patents and Topics on Imaging (Discontinued) High Fat Meal Increase of IL-17 is Prevented by Ingestion of Fruit Juice Drink in Healthy Overweight Subjects
Current Pharmaceutical Design Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications
Recent Advances in Cardiovascular Drug Discovery (Discontinued) The Role of Transforming Growth Factor β1 in the Regulation of Blood Pressure
Current Hypertension Reviews Common and Less Common Peripheral Nerve Disorders Associated with Diabetes
Current Diabetes Reviews Treatment of Cardiovascular Risk Factors in Women
Current Medicinal Chemistry Gene Therapy for Familial Hypercholesterolemia
Current Pharmaceutical Design Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System
CNS & Neurological Disorders - Drug Targets The Crosstalk between Gut Inflammation and Gastrointestinal Disorders During Acute Pancreatitis
Current Pharmaceutical Design Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) Endoplasmic Reticulum Stress, Diabetes Mellitus, and Tissue Injury
Current Protein & Peptide Science Protective Effects of TRPV1 Activation Against Cardiac Ischemia/ Reperfusion Injury is Blunted by Diet-Induced Obesity
Cardiovascular & Hematological Disorders-Drug Targets Hepatic Injury to the Newborn Liver Due to Drugs
Current Pharmaceutical Design Diagnosis of Systemic Lupus Erythematosus in an Unusual Presentation: What a Primary Care Physician Should Know
Current Rheumatology Reviews Potential Genetic Therapies for Acute Lung Injury
Current Gene Therapy The Role of T and B Cells in Atherosclerosis: Potential Clinical Implications
Current Pharmaceutical Design Mechanisms of Cardiovascular Changes in an Experimental Model of Syndrome X and Pharmacological Intervention on the Renin-Angiotensin- System
Current Vascular Pharmacology Thiazolidinediones and Type 2 Diabetes: From Cellular Targets to Cardiovascular Benefit
Current Drug Targets Giant Cell Arteritis - Beyond the Headache
Current Rheumatology Reviews Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders
Current Drug Targets